Skip to content

Proinflammatory monocytes and fractalkine – new markers of early atherosclerosis ?

Proinflammatory monocytes and fractalkine – new markers of early atherosclerosis ? - CARE FOR HOME

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00039691
Enrollment
700
Registered
2026-03-26
Start date
2008-12-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18

Interventions

Group 1: CKD patients in KDIGO GFR stages G2–G4 are followed from baseline and then annually over a period of five years with regard to the occurrence of cardiac, cardiovascular, and renal events. At

Sponsors

Universität des Saarlandes
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: CKD KDIGO GFR category G2-G4

Exclusion criteria

Exclusion criteria: active malignancy; immunosuppressive therapy; human immunodeficiency virus infection; acute kidney disease (defined as an increase of plasma creatinine more than 50 % within four weeks); pregnancy, age 50 mg/l and/or systemic antibiotic therapy); prior kidney transplantation; and hematologic malignancy.

Design outcomes

Primary

MeasureTime frame
Endpoint: First occurrence within a follow-up period of up to five years of the composite endpoint consisting of an atherosclerotic event (defined as acute myocardial infarction, coronary, peripheral arterial, or cerebrovascular revascularization, stroke with symptoms over 24 hours, non-traumatic amputation above the ankle) and/or death from any cause. Assessment is performed once per year with a questionnaire.

Secondary

MeasureTime frame
1. CKD progression (halving of eGFR, introduction of dialysis and/or renal death) 2. heart failure (hospitalization due to acute cardial decompensation)

Countries

Germany

Contacts

Public ContactInsa E. Emrich

Universität des Saarlandes, Uniklinikum des Saarlandes

insa.emrich@uks.eu0049 6841 16 15 000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026